Therapy for immune thrombocytopenia (ITP) differs for different patients: some do not require any treatment; others have a spontaneous remission or respond to first-line therapy with glucocorticoids and/or intravenous immune globulin (IVIG); and others continue to have severe thrombocytopenia and/or bleeding, necessitating additional therapy.
Here we discuss our approach to management of adults with ITP who require additional therapy beyond glucocorticoids and IVIG (ie, second- and third-line therapy). The clinical manifestations, diagnosis, and initial treatment of adults and children presenting with ITP are discussed in detail separately.
●(See "Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis".)
●(See "Immune thrombocytopenia (ITP) in adults: Initial treatment and prognosis".)
●(See "Immune thrombocytopenia (ITP) in children: Initial management".)